Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial

European Journal of Preventive Cardiology

Volumn 22, Issue 6, 2015, Pages 734-742

  Patel, Manesh R ^a   Becker, Richard C ^a,b   Wojdyla, Daniel M ^a   Emanuelsson, Hakan ^c   Hiatt, William R ^d   Horrow, Jay ^e   Husted, Steen ^f   Mahaffey, Kenneth W ^g   Steg, P Gabriel ^h,i,j,k   Storey, Robert F ^l   Wallentin, Lars ^m   James, Stefan K ^m  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF COLORADO   (United States)

^e ASTRAZENECA   (United Kingdom)

^f REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h INSERM   (France)

ⁱ BICHAT HOSPITAL   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k ROYAL BROMPTON HOSPITAL   (United Kingdom)

^l UNIVERSITY OF SHEFFIELD   (United Kingdom)

^m UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

acute coronary syndrome; Peripheral artery disease; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT RISK; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; KAPLAN MEIER METHOD; MORTALITY; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; STROKE; TIME; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929074308     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314533215     Document Type: Article

References (26)

1. Deepak L, Bhatt DL, Peterson ED, et al. Prior polyvascular disease: Risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009; 10: 1195-1202
2. Froehlich JB, Mukherjee D, Avezum A, et al. GRACE Investigators. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes: the global registry of acute coronary events (grace). Am Heart J. 2006; 151: 1123-1128
3. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2011; 58: 2020-2045
4. Olin JW, Allie DE, Belkin M, et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. Vasc Med. 2010; 15: 481-512
5. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502
6. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet. 1996; 348: 1329-1339
7. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The onset/offset study. Circulation. 2009; 120: 2577-2585
8. Storey RF, Angiolillo D, Patil SB, et al. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO platelet substudy. J Am Coll Cardiol. 2010; 56: 1456-1462
9. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2009; 361: 1045-1057
10. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2009; 157: 599-605
11. Cotter G, Cannon CP, McCabe CH, et al. OPUS-TIMI 16 Investigators. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction (OPUS-TIMI) 16 study. Am Heart J. 2003; 145: 622-627
12. Spencer FA, Lessard D, Doubeni C, et al. Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting. Am Heart J. 2007; 153: 140-146
13. Guerrero M, Harjai K, Stone GW, et al. Usefulness of the presence of peripheral vascular disease in predicting mortality in acute myocardial infarction patients treated with primary angioplasty (from the primary angioplasty in myocardial infarction database). Am J Cardiol. 2005; 96: 649-654
14. Mukherjee D, Eagle KA, Kline-Rogers E, et al. GRACE Investigators. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the global registry of acute coronary events). Am J Cardiol. 2007; 100: 1-6
15. Pastor-Perez FJ, Soria-Arcos F, Morillas-Blasco P, et al. Additive value of diabetes and peripheral arterial disease in the risk stratification of patients admitted after an acute coronary syndrome: A subanalysis of the PAMISCA study. Int J Clin Pract. 2009; 63: 1314-1319
16. Saw J, Bhatt DL, Moliterno DJ, et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006; 48: 1567-1572
17. Steg PG, Bhatt DL, Wilson PW, et al. REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197-1206
18. Bhatt DL, Eagle KA, Ohman EM, et al. REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350-1357
19. Granger CB, Goldberg RJ, Dabbous O, et al. Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003; 163: 2345-2353
20. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000; 102: 2031-2037
21. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000; 101: 2557-2567
22. Brilakis ES, Hernandez AF, Dai D, et al. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: Results from the Get with the guidelines program. Circulation. 2009; 120: 560-567
23. Gasse C, Jacobsen J, Larsen AC, et al. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction. Eur J Vasc Endovasc Surg. 2008; 35: 51-58
24. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). Circulation. 2006; 113: e463-e654
25. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009; 301: 1909-1919
26. Cacoub PP, Bhatt DL, Steg PG, et al. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30: 192-201